EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Potential synergy between GLP-1 receptor agonists and follicle-stimulating hormone in improving spermatogenesis: biological rationale and future directions

Sandro La Vignera, Aldo E Calogero, Rossella Cannarella, Andrea Crafia, Federica Barbagallo, Rosita A Condorelli

Frontiers in Endocrinology · 02.11.2026 · 17

DOI: 10.3389/fendo.2026.1997083 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Endocrinology, online erschienen am 02.11.2026. Verfasst von Sandro La Vignera und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy. Hauptthemen laut MEDLINE: Spermatogenesis, Glucagon-Like Peptide-1 Receptor Agonists, Infertility, Male, Follicle Stimulating Hormone. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Male infertility represents a significant global health burden, with obesity and metabolic dysfunction emerging as major contributors to impaired spermatogenesis and functional hypogonadism. Follicle-stimulating hormone (FSH) has been employed to stimulate spermatogenesis in selected patients, while glucagon-like peptide-1 receptor agonists (GLP-1RAs) have demonstrated beneficial effects on male reproductive function beyond their metabolic actions. Understanding their potential synergistic mechanisms may open new therapeutic avenues.

Methods

We conducted a narrative review examining FSH signaling in spermatogenesis, GLP-1 receptor expression in testicular cells, the impact of obesity on male reproduction, and the molecular mechanisms underlying GLP-1RA–FSH synergistic interactions. Relevant studies were identified through a structured non-systematic search of PubMed/MEDLINE and Scopus (last searched September 2025), using search terms including ‘GLP-1 receptor agonists’, ‘semaglutide’, ‘liraglutide’, ‘follicle-stimulating hormone’, ‘FSH’, ‘spermatogenesis’, ‘male infertility’, ‘obesity’, and ‘functional hypogonadism’, supplemented by manual reference screening. No formal quality appraisal tool was applied, consistent with the narrative review format.

Results

FSH acts primarily through Sertoli cells via cAMP-dependent pathways, with clinical efficacy demonstrated in men with idiopathic oligozoospermia and hypogonadotropic hypogonadism. GLP-1 receptors are expressed in Leydig, Sertoli, and germ cells; GLP-1RAs improve testosterone, gonadotropin secretion, and sperm parameters predominantly in obese men with functional hypogonadism. Obesity impairs spermatogenesis through HPG axis suppression, insulin resistance, aromatase activity, oxidative stress, and chronic inflammation. GLP-1RAs may potentiate FSH action through shared signaling pathways (cAMP, PI3K/Akt, AMPK), enhanced Sertoli cell metabolism, and restoration of the HPG axis in metabolically impaired men.

Conclusions

The convergence of GLP-1 and FSH signaling in testicular cells, combined with GLP-1RA metabolic benefits in obese infertile men, provides a strong biological rationale for combination therapy. Preliminary clinical evidence supports GLP-1RA efficacy in improving reproductive outcomes in men with obesity-associated hypogonadism; this benefit appears conditional on pre-existing metabolic dysfunction, with negligible or mildly adverse effects in eugonadal metabolically healthy men. Prospective randomized controlled trials are urgently needed to evaluate combined GLP-1RA and FSH therapy, with particular attention to responder profiles and long-term reproductive outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SpermatogenesisGlucagon-Like Peptide-1 Receptor AgonistsInfertility, MaleFollicle Stimulating HormoneHumansMaleAnimalsObesityHypothalamic-Pituitary-Gonadal AxisGlucagon-Like Peptide-1 Receptor

Stichwörter der Autor:innen

GLP-1 receptor agonistsSertoli cellsfollicle-stimulating hormonefunctional hypogonadismmale infertilityobesitysemaglutidespermatogenesis

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsFollicle Stimulating HormoneGlucagon-Like Peptide-1 Receptor

Autor:innen und Institutionen

  • Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.

Zitieren

APA

La Vignera, S., Calogero, A. E., Cannarella, R., Crafia, A., Barbagallo, F., & Condorelli, R. A. (2026). Potential synergy between GLP-1 receptor agonists and follicle-stimulating hormone in improving spermatogenesis: biological rationale and future directions. Frontiers in Endocrinology, 17. https://doi.org/10.3389/fendo.2026.1997083

Vancouver

La Vignera S, Calogero AE, Cannarella R, Crafia A, Barbagallo F, Condorelli RA. Potential synergy between GLP-1 receptor agonists and follicle-stimulating hormone in improving spermatogenesis: biological rationale and future directions. Frontiers in Endocrinology. 2026;17. doi:10.3389/fendo.2026.1997083

BibTeX
@article{LaVignera2026,
  author = {La Vignera, Sandro and Calogero, Aldo E and Cannarella, Rossella and Crafia, Andrea and Barbagallo, Federica and Condorelli, Rosita A},
  title = {Potential synergy between GLP-1 receptor agonists and follicle-stimulating hormone in improving spermatogenesis: biological rationale and future directions},
  journal = {Frontiers in Endocrinology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fendo.2026.1997083}
}
Kostenlos starten →